Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Parvesh Bansal

Pulmonary Disease Melbourne, FL Medical Doctor

NPI 1548293442 CMS profile 25009

1400 Pine St, Suite A, Melbourne, FL 32901

Open in the dashboard

General payments

$8,254

353 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Parvesh Bansal of Melbourne, FL is reported in the CMS Open Payments database as having received $8,254 across 353 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,751 60
2024 General $1,227 49
2023 General $1,365 50
2022 General $1,072 48
2021 General $1,021 50
2020 General $850 44
2019 General $969 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Parvesh Bansal
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Parvesh Bansal were reported at $1,751. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Parvesh Bansal Pulmonary Disease median Middle half National median
2019 $969 $377 $109–$1,340 $163
2020 $850 $230 $56–$907 $114
2021 $1,021 $269 $68–$1,072 $132
2022 $1,072 $390 $100–$1,457 $149
2023 $1,365 $419 $114–$1,659 $160
2024 $1,227 $476 $123–$1,818 $164
2025 $1,751 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,928 77 payments
  2. GlaxoSmithKline, LLC. $1,580 97 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $981 51 payments
  4. Jazz Pharmaceuticals Inc. $775 25 payments
  5. Harmony Biosciences LLC $641 17 payments
  6. Insmed, Inc. $209 10 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $197 9 payments
  8. Inspire Medical Systems, Inc. $189 4 payments
  9. Philips Electronics North America Corporation $187 8 payments
  10. Pulmonx Corporation $161 3 payments
  11. Other $1,406 52 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,950 346 payments
  2. Education $304 7 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $1,137 74 payments
  2. BREZTRI $653 24 payments
  3. XYWAV $599 20 payments
  4. AIRSUPRA $590 17 payments
  5. STIOLTO RESPIMAT $329 15 payments
  6. SPIRIVA RESPIMAT $265 17 payments
  7. WAKIX $264 6 payments
  8. AREXVY $259 12 payments
  9. OFEV $238 13 payments
  10. TEZSPIRE $216 9 payments
  11. Other $4,473 193 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,385

Median for Pulmonary Disease: 936

Drug cost

$461,063

Median for Pulmonary Disease: $487,987

Branded share of claims

58.6%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 187 $205,188
Spiriva Respimat Tiotropium Bromide Brand 44 $42,519
Breo Ellipta Fluticasone/Vilanterol Brand 63 $40,712
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 35 $31,429
Arnuity Ellipta Fluticasone Furoate Brand 109 $30,611
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 27 $30,472
Spiriva Handihaler Tiotropium Bromide Brand 14 $14,859
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 18 $10,602
Incruse Ellipta Umeclidinium Bromide Brand 16 $8,342
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 21 $6,931

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 25 billing codes

Paid by Medicare

$274,430

Medicare's payments for the services billed

Medicare patients

764

Average age 75

Services billed

5,742

394 women, 370 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
COPD 45%
Diabetes 41%
Ischemic heart disease 37%
Chronic kidney disease 36%
Depression 27%
Heart failure 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $281
$281 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $153
$153 187 —
WAKIX
  • Harmony Biosciences LLC $90
$90 — —
Arikayce
  • Insmed, Inc. $64
$64 — —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $62
$62 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

353 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record